46 results
8-K
OCUL
Ocular Therapeutix Inc
4 Oct 23
Regulation FD Disclosure
9:02am
, 2023, Antony Mattessich, Chief Executive Officer of Ocular Therapeutix, Inc. (the “Company”) will make a presentation at the EURETINA Innovation
8-K
OCUL
Ocular Therapeutix Inc
16 Jul 20
Results of Operations and Financial Condition
9:17am
to present a company overview over the internet at the Ophthalmology Innovation Summit Virtual Public Company Showcase on July 16, 2020. Information
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
16 Jul 20
Results of Operations and Financial Condition
9:17am
Ophthalmology Innovation Summit (OIS) Virtual Public Company Showcase July 16, 2020
FORWARD LOOKING STATEMENTS Any statements in this presentation about future …
INTRACANALICULAR INSERTS AN INNOVATION IN DRUG DELIVERY TO THE OCULAR SURFACE 12
OTX-CSI (CYCLOSPORINE INTRACANALICULAR SUSTAINED RELEASE THERAPY FOR DRY
8-K
OCUL
Ocular Therapeutix Inc
25 Mar 19
Departure of Directors or Certain Officers
8:06am
and Medical Innovation Sciences. Ms. Williams received a B.S. in Nursing from the University of Iowa and a M.B.A. from the Washington University John
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
17 Jul 20
DEXTENZA® Sets Billable Insert In-Market Sales Record in June and Company Announces Preliminary Second Quarter 2020 Net Product Revenue
7:34am
Exhibit 99.1
Ocular Therapeutix Presents at the 12th Annual Ophthalmology Innovation Summit (OIS)
DEXTENZA® Sets Billable Insert In-Market Sales
8-K
EX-99.1
56kop7bg 3ps
4 Oct 23
Regulation FD Disclosure
9:02am
8-K
EX-99.1
sxwak1
11 Jan 21
Results of Operations and Financial Condition
12:00am